AR029624A1 - Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene - Google Patents

Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene

Info

Publication number
AR029624A1
AR029624A1 ARP000101687A ARP000101687A AR029624A1 AR 029624 A1 AR029624 A1 AR 029624A1 AR P000101687 A ARP000101687 A AR P000101687A AR P000101687 A ARP000101687 A AR P000101687A AR 029624 A1 AR029624 A1 AR 029624A1
Authority
AR
Argentina
Prior art keywords
antibodies
pharmaceutical composition
fragments
composition containing
idiotipic
Prior art date
Application number
ARP000101687A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR029624A1 publication Critical patent/AR029624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

Anticuerpos y fragmentos de anticuerpo que son anti-idiotípicos para un anticuerpo que interfiere con el enlace de la region C3 de IgE a su receptor de alta afinidad (mimocuerpos), particularmente que son anti-idiotípicos) para BSW17 (mimocuerpos BSW17), así como composicion farmacéutica, especialmente vacunas que los contienen, el tratamiento de enfermedades mediadas por IgE.
ARP000101687A 1999-04-14 2000-04-12 Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene AR029624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9908533.4A GB9908533D0 (en) 1999-04-14 1999-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR029624A1 true AR029624A1 (es) 2003-07-10

Family

ID=10851525

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101687A AR029624A1 (es) 1999-04-14 2000-04-12 Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene

Country Status (29)

Country Link
US (1) US7041288B2 (es)
EP (1) EP1169353B1 (es)
JP (1) JP4109829B2 (es)
KR (1) KR100492202B1 (es)
CN (1) CN1268644C (es)
AR (1) AR029624A1 (es)
AT (1) ATE392437T1 (es)
AU (1) AU767712B2 (es)
BR (1) BR0009781A (es)
CA (1) CA2363991C (es)
CO (1) CO5241329A1 (es)
CZ (1) CZ20013673A3 (es)
DE (1) DE60038608T2 (es)
ES (1) ES2302693T3 (es)
GB (1) GB9908533D0 (es)
HK (1) HK1044544B (es)
HU (1) HUP0200713A2 (es)
IL (2) IL145507A0 (es)
MX (1) MXPA01010348A (es)
MY (1) MY141459A (es)
NO (1) NO20014936L (es)
PE (1) PE20010046A1 (es)
PL (1) PL350676A1 (es)
PT (1) PT1169353E (es)
RU (1) RU2253655C2 (es)
SK (1) SK14592001A3 (es)
TR (1) TR200102877T2 (es)
WO (1) WO2000063252A1 (es)
ZA (1) ZA200107906B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
SE0101093D0 (sv) * 2001-03-28 2001-03-28 Pharmacia Diagnostics Ab Novel compound for treatment of allergy and asthma
US7604955B2 (en) 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
BRPI0720001A2 (pt) * 2006-12-14 2013-12-24 Schering Plough Ltd Proteína linfopoietin estromal tímica canina e usos da mesma
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
AU2010290931B2 (en) * 2009-09-03 2014-02-06 Pfizer Vaccines Llc PCSK9 vaccine
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
BR112021016791A2 (pt) * 2019-02-26 2021-11-16 Sorrento Therapeutics Inc Proteínas de ligação de antígenos que se ligam a bcma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45285T1 (de) 1983-11-07 1989-08-15 Wistar Inst Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JP2724625B2 (ja) * 1987-12-31 1998-03-09 タノックス・バイオシステムズ・インコーポレーテッド ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
CA2074089C (en) 1990-01-23 2001-04-10 Tse-Wen Chang Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
IT1238286B (it) 1990-03-26 1993-07-12 Dispositivo sensore di livello del liquido per caldaie a vapore.
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
JPH08502260A (ja) 1992-09-30 1996-03-12 ザ スクリップス リサーチ インスティテュート ヒト免疫不全ウイルスに対するヒト中和モノクローナル抗体
ES2190799T5 (es) * 1996-03-01 2008-08-16 Novartis Ag Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.
JPH11174A (ja) * 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
AU762711C (en) 1998-04-24 2004-05-27 Fang Fang Identifying peptide ligands of target proteins with target complementary library technology (TCLT)

Also Published As

Publication number Publication date
PT1169353E (pt) 2008-07-14
HK1044544B (zh) 2008-11-21
MXPA01010348A (es) 2002-10-23
HK1044544A1 (en) 2002-10-25
MY141459A (en) 2010-04-30
HUP0200713A2 (en) 2002-07-29
CA2363991C (en) 2010-06-08
PL350676A1 (en) 2003-01-27
KR100492202B1 (ko) 2005-06-03
CN1268644C (zh) 2006-08-09
TR200102877T2 (tr) 2002-01-21
NO20014936D0 (no) 2001-10-10
JP4109829B2 (ja) 2008-07-02
RU2253655C2 (ru) 2005-06-10
ZA200107906B (en) 2003-08-27
CA2363991A1 (en) 2000-10-26
WO2000063252A1 (en) 2000-10-26
CZ20013673A3 (cs) 2002-05-15
SK14592001A3 (sk) 2002-05-09
PE20010046A1 (es) 2001-02-23
DE60038608T2 (de) 2009-06-10
KR20020007366A (ko) 2002-01-26
ATE392437T1 (de) 2008-05-15
BR0009781A (pt) 2002-01-08
IL145507A0 (en) 2002-06-30
ES2302693T3 (es) 2008-08-01
NO20014936L (no) 2001-12-03
AU3966000A (en) 2000-11-02
JP2002544125A (ja) 2002-12-24
EP1169353B1 (en) 2008-04-16
US20020141989A1 (en) 2002-10-03
GB9908533D0 (en) 1999-06-09
AU767712B2 (en) 2003-11-20
CN1346372A (zh) 2002-04-24
CO5241329A1 (es) 2003-01-31
US7041288B2 (en) 2006-05-09
EP1169353A1 (en) 2002-01-09
DE60038608D1 (de) 2008-05-29
IL145507A (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AR029624A1 (es) Anticuerpos o fragmentos de anticuerpos anti-idiotipicos recombinantes y composicion farmaceutica que los contiene
LU93274I2 (fr) Elotuzumab
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
CR10878A (es) Anticuerpos para cd40 (divisional de exp. 7343)
ES2154738T3 (es) Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
DE69800716T2 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
CL2010000018A1 (es) Fragmentos de peptido amiloide beta(ab) ab 1-7 y ab 3-7 ligados a un peptido portador, composicion farmaceutica que lo comprende y su uso para tratar la enfermedad de alzheimer
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
BR9807843B1 (pt) heterociclos bicìclicos dissubstituìdos, composições farmacêuticas, uso, bem como processos para preparação das referidas composições e dos referidos compostos.
DK1887016T3 (da) Fragmenter af humant choriongonadotropin (HCG) som immunoregulator
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
ES2115927T3 (es) Compuestos utilizados como blancos.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c

Legal Events

Date Code Title Description
FB Suspension of granting procedure